IE 11 is not supported. For an optimal experience visit our site on another browser.

Achillion Pharmaceuticals Leads Stock Watchlist

/ Source: GlobeNewswire

DALLAS, June 23, 2011 (GLOBE NEWSWIRE) -- announces a stock report featuring Achillion Pharmaceuticals Inc. (Nasdaq:ACHN). The report details the company's recent developments and news, outlines its financial position, and recaps comparative and analyst consensus.

The full report is available at:

Achillion Pharmaceuticals Inc. (ACHN) is a biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for infectious diseases. Within the anti-infective market, it is currently concentrating on the development of antivirals for the treatment of chronic hepatitis C and the development of antibacterials for the treatment of resistant bacterial infections. As of December 31, 2009, ACHN focused on developing three Hepatitis C virus (HCV) drug candidates.

This newsletter has been helping traders make great investment decisions on ACHN; click here for a 25% discount offer.

In the report, the analyst notes:

"Shares of ACHN spiked almost 21% in yesterday's trading after the biopharmaceutical company announced the pricing of the public offering of its common stock. The New Haven, Connecticut-based company said it plans to sell 9.6 million shares at $5.90 a share, down from the previous session's closing price of $6.01."

"Also yesterday, the Company announced that it has initiated patient dosing in segment 2 of its phase II clinical trial of ACH-1625 for the treatment of hepatitis C virus (HCV) for genotype 1 treatment naïve HCV-infected patients. ACH-1625, discovered and advanced by ACH, is a potent small molecule inhibitor of HCV protease, an enzyme necessary for viral replication."

To read the entire report visit:

See what investors are saying about ACHN at

Get breaking news on ACHN at is a small-cap research and investment commentary provider. strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: Disclosure is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. is a Web site wholly owned by BlueWave Advisors, LLC. Neither nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site,, for complete risks and disclosures.

CONTACT: Jay Geller 1-888-307-2850